« Return to News | R&D Trends

Hybrigenics, Servier ink license and research agreement

Tuesday, October 11, 2011 11:38 AM

Hybrigenics and Servier have signed a license and research collaboration agreement in the field of deubiquitinating enzymes (DUBs) applied to oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases.

Hybrigenics will identify and validate new targets among DUBs in these therapeutic areas. Hybrigenics will also screen potential therapeutic agents able to modulate four undisclosed targets, already chosen as exclusive DUBs of interest under the collaboration. Servier will provide the compounds to be screened, develop the selected compounds and commercialize the approved drugs. Hybrigenics’ activities under this collaboration may also lead to the discovery of companion diagnostics, potentially needed for such therapeutic drugs.

During the three years of collaboration, Hybrigenics will receive an upfront payment and research funding totaling EUR four million. Depending on the achievement of pre-defined research, development and registration milestones, Hybrigenics is further eligible to receive payments amounting to EUR 9.5 million for each target successfully leading to registration of a new drug, and to royalties on sales of companion diagnostic kits.

“The inhibition of DUBs is a very innovative approach to stimulate the degradation of specific intra-cellular proteins, with a clear potential impact in treating cancer and possibly many other diseases. We are very pleased to initiate such collaboration with Hybrigenics, one of the world pioneers in this domain,” said Bernard Marchand, PhD, head of Servier Research.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.